The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Effective postoperative pain control is essential for patients and inadequate postoperative pain relief can cause mental and psychological sufferings. Despite the growing concern on postoperative pain management, acute postoperative pain is still poorly managed. Though numerous clinical practice guidelines for postoperative pain management have been published throughout the last decades, inadequate pain relief remain a big health care issue. Sufentanil has been used as satisfied pain control drug because of its strong potency of analgesia for a long while. But its use in patient controlled intravenous analgesia (PCIA) has not been clarified. And the dilemma of safety concern and insufficient dosage of analgesic is a common problem. Thus the investigators design this prospective randomized controlled double blinded trial to observe the efficacy and the optimal dose of sufentanil in PCIA in patients underwent moderate surgery for the purpose of providing reference in clinical practice.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University
• Treatments: Cisatracurium; Dsuvia; Midazolam; Propofol; Sufentanil

Criteria

Inclusion Criteria:

• 20 to 75 years old,

• BMI 18 to 28kg/m2,

• ASA I to II grade,

• anticipated surgery duration within 4hrs,

• agree to sign consent paper.

Exclusion Criteria:

• severe respiratory,

• cardiovascular or neurological disease,

• hepatic or renal dysfunction,

• psychiatric history or with unstable mental state,

• drug addiction or dependence